Work

Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.5074

Authors: Arun Azad, Taro Iguchi, Boris Alekseev, Neal D. Shore, Jennifer Sugg, Gabriel P. Haas, Michele Wozniak, Thomas O'Brien, Douglas Laird, Arnulf Stenzl, Andrew J. Armstrong

Institutions: Peter MacCallum Cancer Centre, Kanazawa Medical University, P.A. Hertzen Moscow Oncology Research Institute, Carolina Urologic Research Center, Astellas Pharma (United States), Pfizer (United States), University of Tübingen, Duke Medical Center, Duke Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286293836

Cites:

Cited by:

Related to: 10